<DOC>
	<DOC>NCT02488759</DOC>
	<brief_summary>The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: - Anal canal cancer - Cervical cancer - Epstein Barr Virus (EBV) positive gastric cancer - HPV positive and negative squamous cell cancer of the head and neck (SCCHN) - Merkel Cell Cancer - Nasopharyngeal cancer (NPC) - Penile cancer - Vaginal and vulvar cancer</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors</brief_title>
	<detailed_description />
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types): 1. Merkel Cell Carcinoma 2. Gastric or GastroEsophageal junction carcinoma 3. Nasopharyngeal Carcinoma 4. Squamous cell carcinoma of the cervix, vagina, or vulva 5. Squamous cell carcinoma of the Head and Neck 6. Squamous cell carcinoma of the anal canal and penile Measurable disease by CT or MRI Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen) Men and women of age 18 or older Active brain metastases or leptomeningeal metastases Patients with active, known or suspected autoimmune disease Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications Patients with hepatitis Patients with HIV Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>